Copyright Reports & Markets. All rights reserved.

Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019

Buy now

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview

              Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development

                Products under Development by Stage of Development

                  Products under Development by Therapy Area

                    Products under Development by Indication

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment

                            Assessment by Mechanism of Action

                              Assessment by Route of Administration

                                Assessment by Molecule Type

                                  Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development

                                    Addex Therapeutics Ltd

                                      Appello Pharmaceuticals Inc

                                        Bio-Pharm Solutions Co Ltd

                                          Bristol-Myers Squibb Co

                                            Domain Therapeutics SA

                                              H. Lundbeck AS

                                                Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles

                                                  ADX-88178 - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          DT-095435 - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products

                                                                    Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Discontinued Products

                                                                      Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones

                                                                        Featured News & Press Releases

                                                                          Appendix

                                                                            Methodology

                                                                              Coverage

                                                                                Secondary Research

                                                                                  Primary Research

                                                                                    Expert Panel Validation

                                                                                      Contact Us

                                                                                        Disclaimer

                                                                                        Metabotropic Glutamate Receptor 4 - Pipeline Review, H1 2020

                                                                                        Summary

                                                                                        According to the recently published report 'Metabotropic Glutamate Receptor 4 – Pipeline Review, H1 2020'; Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

                                                                                        Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

                                                                                        The report 'Metabotropic Glutamate Receptor 4 – Pipeline Review, H1 2020' outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

                                                                                        It also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Parkinson's Disease, Alzheimer's Disease, Anxiety Disorders, Drug-Induced Dyskinesia, Infantile Spasm (West Syndrome), Opium (Opioid) Addiction and Status Epilepticus.

                                                                                        Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                        Scope

                                                                                        - The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
                                                                                        - The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
                                                                                        - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
                                                                                        - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
                                                                                        - The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects
                                                                                        - The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
                                                                                        - The report summarizes all the dormant and discontinued pipeline projects
                                                                                        - The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

                                                                                        Reasons to Buy

                                                                                        - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
                                                                                        - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
                                                                                        - Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
                                                                                        - Identify the use of drugs for target identification and drug repurposing
                                                                                        - Identify potential new clients or partners in the target demographic
                                                                                        - Develop strategic initiatives by understanding the focus areas of leading companies
                                                                                        - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
                                                                                        - Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape
                                                                                        - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

                                                                                        Buy now